Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN.VN)

Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 628,947
  • Shares Outstanding, K 79,213
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,006 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings $-0.06 on 11/24/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.650 +37.88%
on 12/16/25
8.490 -8.24%
on 01/08/26
+1.790 (+29.83%)
since 12/12/25
3-Month
3.200 +143.44%
on 11/06/25
8.490 -8.24%
on 01/08/26
+3.100 (+66.10%)
since 10/10/25
52-Week
2.570 +203.11%
on 06/02/25
8.490 -8.24%
on 01/08/26
+4.700 (+152.10%)
since 01/10/25

Most Recent Stories

More News
NervGen Pharma Begins Trading on Nasdaq Today

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 5.65 (-1.74%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placeboParticipant-reported...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. Food...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsReinforced...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial ResultsVancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV:...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.790 (-1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial...

See More

Key Turning Points

3rd Resistance Point 8.387
2nd Resistance Point 8.243
1st Resistance Point 8.017
Last Price 7.790
1st Support Level 7.647
2nd Support Level 7.503
3rd Support Level 7.277

See More

52-Week High 8.490
Last Price 7.790
Fibonacci 61.8% 6.229
Fibonacci 50% 5.530
Fibonacci 38.2% 4.831
52-Week Low 2.570

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar